Nausea and Vomiting Induced by Cytostatic Agents

References

• Siegel L J, Longo D L. The control of chemotherapy-induced emesis. Ann Intern Med 1981; 95: 352–359
   PubMed Web of Science ®Google Scholar
• Borison H L, Wang S C. Functional localization of central coordinating mechanism for emesis in cat. J Neurophysiol 1949; 12: 305–313
   PubMed Web of Science ®Google Scholar
• Borison H L, Wang S C. Physiology and pharmacology of vomiting. Pharmacol Rev 1953; 5: 193–230
   PubMed Web of Science ®Google Scholar
• Wang S C. Emetic and antiemetic drugs. Physiological pharmacology, W S Root, F G Hofman. Academic Press, New York 1965; Vol. II: 255–328
   Google Scholar
• Browne D C, Sparks R. Vomiting mechanisms: a clinical study of thiethylperazine. South Med J 1961; 54: 953–961
   Web of Science ®Google Scholar
• Tau L K, Miller A O. Innervation of periesophageal region of cat's diaphragm: implication for studies of control of vomiting. Neurosci Lett 1986; 68: 334–339
   PubMed Web of Science ®Google Scholar
• Caene D B. Neutrotransmitters, neuromodulators and neurohormones. Neurology 1979; 29: 1517–1521
   PubMed Web of Science ®Google Scholar
• Harris A L. Cytotoxic therapy induced vomiting is mediated via enkephalin pathways. Lancet 1982; 1: 714–716
   PubMed Web of Science ®Google Scholar
• McCarthy L E, Borison H L. Cisplatin induced vomiting eliminated by ablation of the area post-rema in cats. Cancer Treat Rep 1984; 68: 401–404
   PubMedGoogle Scholar
• Akwari O E. The gastrointestinal tract in chemotherapy induced emesis. A final common pathway. Drugs 1983; 25: 18–34
   PubMed Web of Science ®Google Scholar
• Morrow G R, Morrell C. Behavioral treatment for anticipatory nausea and vomiting induced by cancer chemotherapy. N Engl J Med 1982; 307: 1476–1480
   PubMed Web of Science ®Google Scholar
• Morrow G R. The effect of a susceptibility to motion sickness on the side effects of cancer chemotherapy. Cancer 1985; 55: 766–770
   PubMed Web of Science ®Google Scholar
• Moher D, Arthur A Z, Pater J L. Anticipatory nausea and/or vomiting. Cancer Treat Rev 1984; 11: 257–264
   PubMed Web of Science ®Google Scholar
• Demster C R, Balson P, Dhalen B T. Supportive hypnotherapy during the radical treatment of malignancies. Int J Clin Exp Hypn 1976; 24: 1–9
   PubMed Web of Science ®Google Scholar
• Morrow G R, Morrell C. Behaviour treatment for the anticipatory nausea and vomiting induced by cancer chemotherapy. N Engl J Med 1982; 307: 1476–1480
   PubMed Web of Science ®Google Scholar
• Carpenter S O, Briggs D B, Strominger N. Behavioral and electrophysiological studies of peptide-induced emesis in dogs. Fed Proc 1984; 43: 2952–2954
   PubMedGoogle Scholar
• Shields K G, Ballinger C M, Hathaway B N. Antiemetic effectiveness of haloperidol in human volunteers challenged with apomorphine. Anesth Analg 1971; 50: 1017–1027
   PubMed Web of Science ®Google Scholar
• Brogden R N, Carmine A A, Heel R C, et al. Dom-peridone. A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic. Drugs 1982; 24: 360–400
   PubMed Web of Science ®Google Scholar
• Tonato M, Foila R, Del Favero A, et al. A pilot study of high dose domperidone as an antiemetic in patients treated with cisplatin. Eur J Cancer Clin Oncol 1985; 21: 807–810
   PubMedGoogle Scholar
• Gralla R J, Itri L M, Pisko S E, et al. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochloperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 1981; 305: 905–990
   PubMed Web of Science ®Google Scholar
• Kris M G, Gralla K J, Tyson L B, et al. Improved control of cisplatin induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Cancer 1985; 55: 527–534
   PubMed Web of Science ®Google Scholar
• Senn H J, Glaus A, Backmann-Mettler I. Effective control of chemotherapy induced nausea and vomiting with oral prednisone and metoclopramide. J Clin Oncol 1984; 2: 320–322
   PubMed Web of Science ®Google Scholar
• Strum S B, McDermed J E, Streng B R, et al. Combination metoclopramide and dexamethasone: an effective anti-emetic regimen in outpatients receiving non-cisplatin chemotherapy. J Clin Oncol 1984; 2: 1057–1063
   PubMed Web of Science ®Google Scholar
• Strum S B, McDermed J E, De Liponi. High dose i.v. metoclopramide versus combination high dose metoclopramide and intravenous dexamethasone in preventing cisplatin-induced nausea and emesis: a single-blind cross over comparison of anti-emetic efficacy. J Clin Oncol 1985; 3: 245–251
   PubMed Web of Science ®Google Scholar
• Gagen M, Gochnour D, Young D, et al. A randomized trial of metoclopramide and a combination of dexamethasone and lorazepam for prevention of chemotherapy induced vomiting. J Clin Oncol 1984; 2: 696–701
   PubMed Web of Science ®Google Scholar
• Anthony L B, Korzely M G, Woodward N J, et al. Anti emetic effect of intravenous metoclopramide in patients receiving cisplatin: a randomized double blind trial. J Clin Oncol 1986; 4: 98–103
   PubMed Web of Science ®Google Scholar
• Sailer R, Hellenbrecht D, Briemann L, et al. Metoclopramide kinetics at high-dose infusion rates for prevention of cisplatin induced emesis. Clin Pharmacol Ther 1985; 37: 43–47
   PubMed Web of Science ®Google Scholar
• Warrington P S, Allan S G, Cornbleet M A, et al. Optimizing anti-emetics in cancer chemotherapy: efficacy of continuous versus intermittent infusion of high-dose metoclopramide in emesis induced by cisplatin. Br Med J 1986; 293: 1334–1337
   PubMedGoogle Scholar
• Sailer R, Hellenbrecht D. Comparison of antiemetic efficacy of two high-dose benzamides, metoclopramide and alizapride, against cisplatin induced emesis. Cancer Treat Rep 1985; 69: 1301–1302
   PubMedGoogle Scholar
• Bishop J F, Olver I N, Wolf M M, et al. Lorazepam: A randomized, double-blind crossover study of a new antiemetic in patients receiving cytotoxic chemotherapy and prochlorperazine. J Clin Oncol 1984; 2: 691–695
   PubMed Web of Science ®Google Scholar
• Fozard J R. Neuronal 5-HT receptors in the periphery. Neuropharmacol 1984; 23: 1473–1486
   PubMed Web of Science ®Google Scholar
• Belpomme D, Rochei H, Maral J, et al. A further study of BRL 43694: duration of maximal antiemetic effects of a single dose. 6th NCI/EORTC symposium on new drugs in cancer therapy, Amsterdam, March, 7–101989, abstract 356
   Google Scholar
• Van Belle S, Cocquyt V, Keppens C, et al. ICS-205–930: a dose finding study in the prevention of cisplatin induced nausea and vomiting. 6th NCI/ EORTC symposium on new drugs in cancer therapy, Amsterdam, March, 7–101989, abstract 357
   Google Scholar
• Brittain R T, Butler A, Coates I H, et al. GR38032F, a novel selective 5HT3 receptor antagonist. Br J Pharmacol 1987; 90: 87
   Google Scholar
• Costall B, Domeney A M, Gunning S J, Naylor R J, Tattersall F D, Tylers M B. GR38032F: a potent and novel inhibitor of cisplatin-induced emesis in the ferret. Br J Pharmacol 1987; 90: 90P
   Google Scholar
• Cunningham D, Hawthorn J, Pople A, Gazet J-C, Ford H T, Coombes R C. Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist. Lancet 1987; 1: 1461–1462
   PubMed Web of Science ®Google Scholar
• De Haan L D, De Mulder P HM, Beex L VAM, Debruyne F MJ, Challoner T, De Pauw B E. The efficacy of GR38032F, an antagonist of 5-hydroxy-tryptamine-3 (5-HT3) in the prophylaxis of cisplatin (CDDP)-induced nausea and vomiting. Eur J Cancer Clin Oncol 1988; 21: 1383–1384
   Google Scholar
• Kris M G, Gralla R J, Clark R A, Tyson L B. Dose ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy. J Clin Oncol 1988; 6: 659–662
   PubMed Web of Science ®Google Scholar
• Van Liessum P A, De Mulder P HM, Kaasa S, Lane-Allman E, Seynaeve C, Verwey J. GR38032F in the prophylaxis of nausea and vomiting induced by cisplatin. Cancer Chem Pharmacol 1989; 23(suppl)267P
   Google Scholar